Takeda pharmaceutical company received this case report from (b) (6)  on 08-SEP-2015 (Ref: GR-JNJFOC-
The following description and the causality were taken as received from the case report provided by (b) (6)
This spontaneous report was received from a physician via a company representative and concerns a male patient 
of unspecified age from Greece.
The patient's weight and height were not reported. The patient's concurrent conditions included multiple myeoma. 
The patient was treated with bortezomib (lyophilized powder, subcutaneous) dose and frequency unspecified 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 340 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
initiated on an unspecified date for multiple myeloma. Non-company suspect drugs included: prednisolone 
(unspecified formulation and route) for multiple myeloma. Concomitant medications were not reported. On an 
unspecified date, the patient experienced coma and wa admitted to hospital. The physicians diagnosed progressive
multifocal leukoencephalopathy and treatment with bortezomib was withdrawn (discontinued). Action taken with 
prednisolone was not reported. The patient was treated with Keppra (levetiracetam) dose and frequency 
unspecified initiated on an unspecified date. The patient was recovering of progressive multifocal 
leukoencephalopathy at the time of report but not completely recovered as the patient was still experiencing 
somnolence.
This report was serious (hospitalization, medically significant).
Company Comment: 
Based on the information provided, a causal association between administration of Velcade and the event cannot 
be excluded.